The Pennant Group (NASDAQ:PNTG) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of The Pennant Group (NASDAQ:PNTG) from a hold rating to a buy rating in a research report released on Saturday.

Several other brokerages have also issued reports on PNTG. Jefferies Financial Group started coverage on shares of The Pennant Group in a report on Friday, October 24th. They issued a “buy” rating and a $30.00 price target for the company. Stephens reiterated an “overweight” rating and issued a $40.00 price objective on shares of The Pennant Group in a report on Thursday, October 9th. Weiss Ratings reiterated a “hold (c+)” rating on shares of The Pennant Group in a report on Wednesday. Truist Financial dropped their price target on shares of The Pennant Group from $32.00 to $28.00 and set a “hold” rating on the stock in a research report on Wednesday, July 16th. Finally, Wells Fargo & Company cut their price objective on The Pennant Group from $31.00 to $29.00 and set an “equal weight” rating for the company in a research report on Thursday, August 14th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $31.75.

The Pennant Group Trading Up 7.5%

Shares of The Pennant Group stock traded up $1.79 on Friday, hitting $25.54. 491,421 shares of the company’s stock traded hands, compared to its average volume of 318,575. The Pennant Group has a one year low of $21.18 and a one year high of $34.27. The firm’s 50-day moving average price is $24.77 and its two-hundred day moving average price is $25.82. The company has a debt-to-equity ratio of 0.08, a current ratio of 1.04 and a quick ratio of 1.21. The stock has a market capitalization of $883.53 million, a PE ratio of 34.05, a price-to-earnings-growth ratio of 2.10 and a beta of 1.39.

The Pennant Group (NASDAQ:PNTG) last issued its earnings results on Wednesday, November 5th. The company reported $0.30 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.29 by $0.01. The firm had revenue of $229.04 million for the quarter, compared to analysts’ expectations of $221.96 million. The Pennant Group had a return on equity of 9.37% and a net margin of 3.15%. The Pennant Group has set its FY 2025 guidance at 1.140-1.180 EPS. On average, research analysts expect that The Pennant Group will post 0.75 EPS for the current fiscal year.

Institutional Trading of The Pennant Group

A number of institutional investors have recently modified their holdings of PNTG. State of Alaska Department of Revenue bought a new position in shares of The Pennant Group in the third quarter worth $54,000. Tower Research Capital LLC TRC lifted its position in The Pennant Group by 161.6% during the second quarter. Tower Research Capital LLC TRC now owns 3,987 shares of the company’s stock worth $119,000 after purchasing an additional 2,463 shares during the period. AlphaQuest LLC acquired a new stake in The Pennant Group during the third quarter worth about $137,000. State of Wyoming increased its holdings in The Pennant Group by 41.3% in the 1st quarter. State of Wyoming now owns 6,170 shares of the company’s stock valued at $155,000 after buying an additional 1,803 shares during the period. Finally, ProShare Advisors LLC bought a new position in The Pennant Group in the 2nd quarter valued at about $207,000. 85.88% of the stock is currently owned by institutional investors.

The Pennant Group Company Profile

The Pennant Group, Inc provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families.